HONEY BROOK, PA — R-V Industries is taking significant strides in the pharmaceutical market. With its upcoming participation in key industry events, including Interphex in New York City (April 1-3) and CPHI in Frankfurt, Germany (October 28-30), R-V underscores its commitment to play a greater role in the global pharmaceutical landscape.
Ackley, Beta Star, Genesis, and R.W. Hartnett, four of R-V’s brands, will be showcased at these prominent trade shows. Their presence demonstrates R-V’s growing influence and dedication to manufacturing excellence. “Our vision is to grow and diversify end markets and find specific niches where our innovative products, facilities, quality, and service create value for customers and growth opportunities for our employees,” said Kirk A. Putt, president and CEO of R-V.
Founded in 1974, R-V first built its reputation in Custom Fabrication, ASME Code Pressure Vessels, Nuclear, Paper, and Power markets. However, its entry into the pharmaceutical sector through strategic acquisitions has significantly shaped its evolution. The pivotal moment came in 2007 with the acquisition of Beta Star Life Science Equipment, a former customer. This acquisition transitioned R-V from a niche industrial equipment manufacturer to a recognized global brand.
R-V continued to extend its capabilities with the addition of Genesis Packaging Technologies in 2017, a leading provider of vial capping and residual seal force testing systems. “Genesis is a great example of how we operate as a series of small companies outperforming larger competitors,” said Putt.
Subsequent acquisitions followed, including MBC Aerosol in 2022, known for its aerosol and bag-on-valve filling systems, and Ackley Machine Corporation in 2023, a specialist in pharmaceutical printing, laser marking, and drilling. Most recently, R-V acquired R.W. Hartnett in 2024, a Philadelphia-based company with a 145-year history of pharmaceutical printing and laser marking.
With six divisions now serving pharmaceutical and related markets, R-V’s momentum is evident. The company attributes over 30% of its $100 million annual revenue to these operations, underscoring its success in leveraging shared resources and driving innovation across divisions.
Through acquisitions and a strong presence at major trade shows, R-V Industries demonstrates its dedication to building on a foundation of expertise while adapting to meet the needs of a dynamic and growing pharmaceutical industry.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.